- Company
- What to do with the loss of drug price cuts?
- by Chon, Seung-Hyun Aug 22, 2023 05:31am
- Pharmaceutical companies are in deep trouble ahead of the end of generic drug price re-evaluation. As each pharmaceutical company announces drug price cuts for as many as 100 or more products, the atmosphere is concentrating on figuring out the size of the loss. Dissatisfaction with the government's indiscriminate re-evaluation of drug price
- Company
- JW Shinyak will resume sales of flu vaccine SKYCellflu
- by Kim, Jin-Gu Aug 22, 2023 05:31am
- On the 21st, JW Shinyak announced that it will resume sales of SK Bioscience’s flu vaccine ‘SKYCellflu Quadrivalent Prefilled Syringe.’ The company signed a joint marketing agreement for ‘SKYCellflu Quadrivalent Prefilled Syringe’ in 2016, and has been responsible for the sales and marketing of the drug at specialized dermatology, ur
- Company
- Luxturna, a one-shot gene therapy product
- by Eo, Yun-Ho Aug 22, 2023 05:31am
- Attention is focusing on whether progress will be made in the discussion on insurance benefits for Luxturna, a one-shot retinal disease treatment. As a result of the coverage, Novartis Korea recently submitted additional supplemental data for Inherited Retinal Dystrophy treatment Luxturna requested by the HIRA. The drug submitted an applicat
- Company
- Generic competition over KRW 56 bil Ibrance market heat up
- by Kim, Jin-Gu Aug 21, 2023 05:37am
- The competition between 5 companies over their generic versions of Pfizer’s breast cancer treatment ‘Ibrance (palbociclib)’ is heating up. Kwang Dong Pharmacuetical, Shinpoong Pharm, Daewoong Pharmaceutical, and Boryung Pharmaceutical each challenged Pfizer to overcome the crystalline form patent and formulation patent of Ibrance. In t
- Company
- Nexviazyme, 1st biobetter to receive preferential pricing
- by Eo, Yun-Ho Aug 21, 2023 05:37am
- The Pompe disease treatment ‘Nexviazyme’ may become the first drug to receive the premium pricing benefit as a biobetter in Korea. According to industry sources, Sanofi-Aventis Korea’s Nexviazyme (avalglucosidase alfa-ngpt) has completed the drug premium pricing calculation process and is soon to receive reimbursement. The drug is lik
- Company
- Hugel HA filler Revolax, obtained product approval
- by Nho, Byung Chul Aug 18, 2023 05:20am
- Hugel, a global total medical aesthetic company, announced on the 17th that it had obtained item permission for the HA filler Revolax from the Thai Food and Drug Administration (TFDA) on the 27th local time. Thailand is the largest beauty/plastic surgery market in Southeast Asia, and according to Decision Resource Group, a global market resea
- Company
- HK Inno.N will comarket Roche’s single-dose Xofluza in KOR
- by Kim, Jin-Gu Aug 18, 2023 05:20am
- With the number of influenza cases rising for the longest period ever after the COVID-19 endemic, Xofluza is expected to open a new paradigm in post-exposure prophylaxis treatment. On the 17th, HK Inno.N announced that it had signed an exclusive distribution and joint sales agreement with Roche Korea for Roche’s ‘Xofluza (baloxavir marb
- Company
- Vabysmo pays attention to entry into reimbursement
- by Eo, Yun-Ho Aug 18, 2023 05:20am
- Vabysmo, a treatment for macular degeneration, stood in front of the final gateway to being listed as an insurance benefit. According to industry sources, Roche Korea's first bispecific antibody treatment Vabysmo for the ophthalmic disease is in negotiations with NHIS. Last month (July), this drug accepted the conditions below the evaluation
- Company
- Bavencio’s reimb may change the Rx paradigm in KOR
- by Hwang, byoung-woo Aug 17, 2023 05:29am
- Changes are arising in the prescription pattern for metastatic urothelial cancer due to the emergence of new treatment options. The reimbursement of Bavencio (avelumab) as a first-line maintenance therapy, increased treatment options for the patients. The drug was first granted reimbursement only as a second-line treatment. As demand for m
- Company
- Retevmo fails reimb at the last stage in KOR
- by Eo, Yun-Ho Aug 17, 2023 05:29am
- The RET-targeted anticancer therapy ‘Retevmo’ failed to pass the last gateway to reimbursement listing in Korea. According to industry sources, the drug pricing negotiations between the National Health Insurance Service and Lilly Korea for the reimbursement of the RET inhibitor Retevmo (selpercatinib) broke down recently. Retevmo,
